For aromatase inhibitor–associated joint pain, randomized evidence provides one example of a management option. In SWOG S1202 (NCT01598298), duloxetine reduced average joint pain scores by 0.82 points more than placebo through 12 weeks (95% CI, −1.24 to −0.40; P = .0002). Adverse events of any grade occurred more frequently with duloxetine, at 78% versus 50%.3
That modest average benefit supports a discussion about suitability, not automatic prescribing. Pharmacists can help evaluate whether symptom relief justifies adding another medication and reassess tolerability after initiation. The trial studied aromatase inhibitor–associated pain; its findings should not be generalized to every survivorship complaint.3
A New Medication Can Change an Established Regimen
Medication reconciliation remains important after initial treatment. Some antidepressants can reduce tamoxifen’s effectiveness, including when prescribed to manage hot flashes. The National Cancer Institute also identifies potential interactions with nonprescription medications such as diphenhydramine and cimetidine.1
Pharmacists should review newly added products against the current endocrine regimen and coordinate any changes with the prescriber. Patients should not independently discontinue an antidepressant or anticancer therapy. A medication that addresses one survivorship concern still needs to fit safely into the broader treatment plan.
Bone Health Needs a Follow-Through Plan
Cancer therapy can add to baseline fracture risk. ASCO’s osteoporosis guideline recommends assessing risk in adults with nonmetastatic cancer and obtaining bone mineral density testing when fracture risk is substantial. Nutrition and exercise should be optimized; when medication is indicated, bisphosphonates or denosumab at osteoporosis-indicated doses are preferred options.4
Pharmacists can help establish whether a bone health assessment has occurred and whether recommended treatment was started. Reviewing calcium and vitamin D intake can also identify gaps or unnecessary duplication. These conversations should connect patients with an individualized plan rather than default to supplements alone.4
Ask About the Symptoms Patients May Leave Unsaid
Vaginal dryness and pain with intercourse can require a private, direct invitation to discuss treatment. ACOG recommends nonhormonal approaches first for individuals with a history of estrogen-dependent breast cancer. Pharmacists can explain the difference between moisturizers used regularly and lubricants used for sexual activity.5
When nonhormonal treatment is inadequate, low-dose vaginal estrogen can be considered after discussion of risks and benefits, including for patients taking tamoxifen. For patients taking aromatase inhibitors, ACOG calls for shared decision-making involving the patient, gynecologist, and oncologist.5
The pharmacist’s role is to support that conversation without implying that every hormonal product is appropriate. Finishing an initial treatment course should come with a clear route back to care when medication concerns arise.2,5
